Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221540 | 0.89 | PREP (0.55) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL221538 | 0.89 | PREP (0.55) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL221539 | 0.89 | PREP (0.55) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL2737914 | 0.86 | PREP (0.49) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL2737913 | 0.86 | PREP (0.54) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL13389110 | 0.84 | TSHR (0.65) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL29302839 | 0.82 | SMN1; SMN2 (0.48) | PREPACE2 | |
| SCHEMBL29302833 | 0.82 | SMN1; SMN2 (0.48) | PREPACE2 | |
| SCHEMBL17009197 | 0.81 | PREP (0.55) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL16282507 | 0.81 | PREP (0.55) | PREPACE2TSHRL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | PREP 672/4885ACE2 22/4885TSHR 3983/4885 |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | PREP 672/4885ACE2 22/4885TSHR 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.